Hemanext has committed its resources to the continuing effort of the transfusion medicine community to save lives and improve patient outcomes. The company is dedicated to improving the quality, safety, efficacy, and cost of transfusion therapy.
View Investor Portal for confidential information and updates. Learn about Hemanext ONE technology.
Hemanext successfully closes series a equity funding round, bringing total raised to more than $100 million
Leading Blood Storage Innovator Expanded Series A Round to Accommodate Interest from Noted Private...
Hemanext Announces that Hypoxic Blood Storage Study has been Recognized as Best Original Research Paper by AABB
Research supports Hemanext’s aim to improve clinical outcomes of transfusion recipients with its...
Hemanext® Inc. Receives CE Mark Certification for Innovative Red Blood Cell (RBC) Processing & Storage System
Company to launch red blood cell (RBC) processing and storage system in select European markets in 2021, with wider distribution in Europe and the Americas in 2022 and future years.
Senior Director of Transfusion Medicine at Johns Hopkins University Brings Global Experience in...
Hemanext Inc. a privately held, US-based medical technology company dedicated to improving the quality, safety, efficacy, and cost of red blood cell (RBC) transfusions, has partnered with Sickle Cell 101 (SC101), a Silicon Valley-based non-profit, to sponsor and promote sickle cell disease (SCD) education.
Curated resources for news, contact information, and newsletter sign-up.